New Translational Research in the Medical Management of Orbital Melanoma

ABSTRACT

New translational research has paved the way for more optimistic management of melanoma. Medications targeting oncogenic signaling cascades and immune regulatory molecules have significantly improved overall survival for patients with metastatic melanoma. While isolated, operable orbital melanoma may still benefit from surgery, there potentially is an opportunity to provide patients with neoadjuvant systemic therapy with sustainable long-term effects. Additionally, patients with non-resectable orbital melanoma can benefit from systemic treatment.

• Dabrafenib
• ipilimumab
• nivolumab
• pembrolizumab
• trametinib
• vemurafinib

DECLARATION OF INTEREST

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.